Early-generation kinase medicines are limited by poor selectivity, off-target effects and the emergence of resistance.

Our founding scientists envisioned a new generation of highly selective kinase medicines that could prolong lives, improve quality of life and prevent disease recurrences, with more potent target inhibition, fewer off-target effects and opportunities for therapeutic combinations.

They worked to build a scalable platform that could yield multiple selective kinase medicines for a wide range of diseases, bringing this innovation to as many patients as possible.

A look inside our labs

Our scientists merge expertise in bioinformatics and structural and cell biology, world-class drug design capabilities and a proprietary library of novel compounds to create a new discovery paradigm. This unique approach enables us to rapidly identify compelling disease targets and design highly selective kinase medicines.

The result is a robust and diverse portfolio of clinical- and research-stage programs targeting genomically defined cancers, rare diseases and cancer immunotherapy. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Meet our Scientists

Luz//
Dean//
Dilinie//
Leni//

Luz Tavera-Mendoza: Senior Scientist, Biology

My path

I completed my Ph.D. at McGill University in Montreal, Canada in the department of Experimental Medicine and my postdoctoral fellowship at the Dana-Farber Cancer Institute of Harvard Medical School in the department of Molecular Oncology.

My experience

My research experience on cellular and molecular biology in the specific context of cancer ultimately led me to Blueprint Medicines.

My biggest achievement

One of my biggest achievements is being the first one to describe that an herbicide previously thought to be safe had the capacity to be an endocrine disruptor at the city of Montreal’s drinking water levels. I joined a large group of scientists who were involved in eventually having this herbicide banned from North America, Europe and Australia. This was very important to me because it helped protect many people’s health as well as the environment.

I also helped uncover a mechanism by which a vitamin D dietary supplementation can help prevent the most common subtype of breast cancer. This is important because most women in the Northern hemisphere have a vitamin D deficiency, and incorporating this small habit can make a substantial impact on women’s health.

My recent scientific publications

Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells,” published in the Proceedings of the National Academy of Sciences in 2017

Vitamin D receptor as a master regulator of the c-MYC/MXD1 network, published in the Proceedings of the National Academy of Sciences in 2012

Genome-wide approaches for identification of nuclear receptor target genes,” published in Nuclear Receptor Signaling in 2006

See Luz's other publications

My Blueprint Medicines

“Patients First” is our most important value. Every scientist working here at Blueprint Medicines shares an intense commitment to making a difference for patients.

Dean Zhang: Senior Scientist, Biochemistry and Biophysics

My path

I was trained as a biochemist and chemical biologist in Dr. Peter Tonge’s group at Stony Brook University. During my five years of Ph.D. training, I tried to understand how drug molecules interact with their protein targets, and how this interaction quantitively translates into drug efficacy.

My experience

After my Ph.D., I joined a pharmaceutical company as a biochemist. There, I was exposed to many different drug discovery projects and learned how to best use my biochemistry background to help discover novel drug molecules. A couple of years in, just when I started doubting if I will ever see a drug that I’ve worked on make it to patients, a biochemist position opened at Blueprint Medicines. I said to myself that this is a rare opportunity where I can work in one of the best small molecule drug discovery organizations, and it might be my best shot to ever deliver a drug to patients. So, I applied and joined.

My biggest achievement

I feel incredibly lucky to be able to apply my background to do a job that’s extremely meaningful and super exciting. It’s already quite an achievement to equip yourself with deep knowledge in any scientific area, but it takes a lot of hard work, perseverance, bravery and more to continue down this road of science and eventually use this knowledge to do a job as meaningful as helping save people’s lives. It sounds like a dream come true because it is a dream that came true.

My Blueprint Medicines

I joined Blueprint because the company stays true to science and has found a way to do drug discovery very efficiently. As a drug discovery scientist, I’ve always dreamt of developing medicines that can impact people’s lives, and Blueprint is the place where I can not only realize this goal, but also do it quickly and many times over.

Dilinie P. Fernando: Scientist II, Medicinal Chemistry

My path

I earned a B.S. in Chemistry from North Dakota State and a M.S. in Organic Chemistry from Washington State University.

My experience

My desire to bring transformative medicines to patients led me to Blueprint Medicines. Prior to joining Blueprint, I worked on kinase inhibitors for the treatment of amyotrophic lateral sclerosis (ALS) and irritable bowel syndrome (IBS) at Amgen Discovery Cambridge and at Pfizer Global Research in Groton, where my efforts contributed to multiple clinical drug candidates. This experience is helping me bring new clinical candidates to patients in need at Blueprint.

My biggest achievement

My career started at Abbott (now AbbVie) in North Chicago, working on process research for clinical candidates from gram to multi kilogram scale. It was my good fortune to have worked in the only operational pilot plant owned by large pharma in the US. One of my most impactful contributions was the design and execution of a novel route to a Phase 2 clinical compound at Abbott. I performed the catalyst screen and route optimization for the first large scale coupling of an unsymmetrical urea to an aryl halide utilizing palladium catalyzed cross-coupling on pilot plant scale (64Kg scale).

My recent scientific publications

Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting,” published in the Journal of Medicinal Chemistry in 2020

“Route Selection and Optimization in the Synthesis of Two Imidazopyridine Inhibitors of DGAT-2,” published in Organic Process Research & Development in 2018

“Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors,” published in ACS Medicinal Chemistry Letters in 2018

See Dilinie's other publications

My Blueprint Medicines

Blueprint’s excellence in the precision oncology space targeting kinases was the primary driver, but seeing the beautiful lab space during my first visit to Blueprint was the deal-closer. I love the Blueprint vibe, culture and vision as small teams take on big dreams to serve patients with unmet medical needs.

Leni S. Jacob: Scientist II

My path

I earned a B.S. in Microbiology from the University of Texas at Austin and a Ph.D. in Genetics & Development from the University of Texas Southwestern Medical Center. I also completed postdoctoral fellowships focusing on metastasis and RNA biology.

My experience

After my undergraduate education, I took a job sequencing DNA for the Human Genome Project, which sparked my interest in research. Through my graduate school and postdoctoral training, I learned I wanted to work on cancer research that had a real impact for patients.

My biggest achievement

During my postdoctoral training, I was able to show that cancer cells don’t need mutations to gain the ability to metastasize. Cancer cells frequently accumulate additional mutations; however, even without permanent changes to their DNA, they can gain the ability to move to another foreign part of the body, evade the immune system and start to form a new tumor. This finding highlighted the importance of expanding our search from genetic alterations to epigenetic and gene expression changes when looking for potential drug targets.

My recent scientific publications

“Non-coding RNA networks in cancer,” published in Nature Reviews Cancer in 2018

“Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer,” published in Nature in 2016

“Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations,” published in Cancer Research in 2015

See Leni's other publications

My Blueprint Medicines

I wanted the research I do to make a difference in patients’ lives, and I knew the innovative and rigorous science at Blueprint Medicines would give me that opportunity.

Luz
Dean
Dilinie
Leni

“We’re entering a new era of precision medicine… we can now rapidly and reproducibly design potent and selective kinase medicines for previously undruggable as well as newly discovered drivers of disease. Combined with recent advances in molecular profiling, we believe these next-generation kinase medicines can quickly achieve clinical proof-of-concept and, ultimately, transform patient care.”

Fouad Namouni, M.D., President, Research & Development

Scientific Advisory Board

Giulio Draetta, M.D., Ph.D.

Director, Institute for Applied Cancer Science at MD Anderson Cancer Center, and Professor of Molecular and Cellular Oncology

Brian Druker, M.D.*

Director, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research

Carlos Garcia-Echeverria, Ph.D.

Global Head of Research Platforms, Sanofi

Scott Lowe, Ph.D.*

Member, Cancer Biology and Genetics Program at Memorial Sloan Kettering Institute Cancer Center, and Chair, Geoffrey Beene Cancer Research Center

Nick Lydon, Ph.D.*

Founder, Granite Biopharma LLC

Charles L. Sawyers, M.D.*

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center